Hyaeyeong Kim

Oct 21, 2024 | biorxiv.org | Joshua Rose |Hyaeyeong Kim |Jessica Von Stetina |Mahant Thangavelu

AbstractMany current genome editing technologies rely on the action of large serine integrases (LSIs) to insert gene-sized DNA sequences into the genome. Bxb1 is the most commonly used LSI for therapeutic efforts, including PASTE, PASSIGE and I-PGI. While Bxb1 demonstrated good activity in vitro in cycling cells, the activity in non-dividing hepatocytes was significantly less efficient.